{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:10:20Z","timestamp":1785769820938,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of Enfortumab vedotin and pembrolizumab (EVP) as a new first-line treatment option for advanced urothelial carcinoma compared to standard chemotherapy (gemcitabine with cisplatin or carboplatin) from the perspective of the US healthcare payer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A partitioned survival model was used to evaluate the cost-effectiveness of EVP compared to standard chemotherapy, incorporating 3 health states: progression-free survival (PFS), progressive disease, and death. The analysis was conducted from the perspective of a US healthcare payer (Veterans Affairs, VA) using a 21-day simulation cycle over a 30-year horizon. Survival data were derived from the EV-302 trial and reconstructed using standard parametric models as well as flexible parametric models. Costs and utility values were sourced from public databases and literature. Sensitivity and scenario analyses assessed the impact of key parameters and different subgroups, with price simulations identifying the threshold price for cost-effectiveness. Total costs (in US dollars), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios were used as main outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the base-case analysis, the lifetime cost of EVP was $989,917, providing an effectiveness of 2.50 QALYs and 4.86 life years. In contrast, chemotherapy cost $166,397 with an effectiveness of 1.49 QALYs and 2.83 life years. The incremental cost-effectiveness ratio for EVP compared to chemotherapy was $814,875 per QALY, indicating it is not cost-effective at the $150,000 threshold. Sensitivity analyses highlighted that the utility for PFS and the pricing of Enfortumab vedotin (EV) significantly impacted cost-effectiveness. Probabilistic sensitivity analysis confirmed chemotherapy as the most cost-effective option across a willingness-to-pay range of $0 to $300,000. Price simulations suggested that EVP would become cost-effective compared to chemotherapy if the price of EV were reduced to $593 per 20\u2009mg. Subgroup analysis showed that at its original price, EV was not cost-effective in any subgroup. However, reducing its price to 22 to 29% of the original made EVP economically viable for various subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>EVP is more effective than chemotherapy but not cost-effective from the perspective of the VA. To achieve cost-effectiveness, a price reduction for EV is necessary.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048312","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:01:54Z","timestamp":1775840514000},"page":"e48312","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness analysis of Enfortumab vedotin and pembrolizumab for advanced urothelial carcinoma"],"prefix":"10.1097","volume":"105","author":[{"given":"Hao","family":"Cheng","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-9374","authenticated-orcid":false,"given":"Ningying","family":"Mao","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection.","volume":"8","author":"Wong","year":"2018","journal-title":"Sci Rep"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs.","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"R4-20260410","first-page":"15","article-title":"Epidemiology of bladder cancer.","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial.","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40164-018-0095-8","article-title":"Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.","volume":"7","author":"McCrea","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.","volume":"115","author":"Yoo","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"R14-20260410","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from nononcology drugs?","volume":"20","author":"Bae","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"17588359211068733","DOI":"10.1177\/17588359211068733","article-title":"Cost-effectiveness of Enfortumab vedotin in previously treated advanced urothelial carcinoma.","volume":"14","author":"Wu","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/13696998.2024.2329019","article-title":"Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.","volume":"27","author":"Brodtkorb","year":"2024","journal-title":"J Med Econ"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/imt-2020-0036","article-title":"Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer.","volume":"12","author":"Li","year":"2020","journal-title":"Immunotherapy"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/cer-2022-0064","article-title":"Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis.","volume":"11","author":"Zhang","year":"2022","journal-title":"J Comp Eff Res"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s41669-022-00348-0","article-title":"Cost-utility of nivolumab plus ipilimumab in first-line treatment of advanced melanoma in the United States: an analysis using long-term overall survival data from checkmate 067.","volume":"6","author":"Baker","year":"2022","journal-title":"PharmacoEcon Open"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.euo.2023.01.011","article-title":"Cost effectiveness of treatment sequences in advanced renal cell carcinoma.","volume":"6","author":"Mason","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40259-023-00586-6","article-title":"Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing.","volume":"37","author":"Shao","year":"2023","journal-title":"BioDrugs"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2021.08.009","article-title":"Cost-effectiveness of cemiplimab versus standard of care in the United States for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression \u226550.","volume":"25","author":"Kuznik","year":"2022","journal-title":"Value Health"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s41669-023-00391-5","article-title":"Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067.","volume":"7","author":"Shao","year":"2023","journal-title":"PharmacoEcon Open"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/his.15287","article-title":"Advances, recognition, and interpretation of molecular heterogeneity among conventional and subtype histology of urothelial carcinoma (UC): a survey among urologic pathologists and comprehensive review of the literature.","volume":"85","author":"Lobo","year":"2024","journal-title":"Histopathology"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jclinpath-2020-206633","article-title":"Methylation study of the Paris system for reporting urinary (TPS) categories.","volume":"74","author":"Pierconti","year":"2021","journal-title":"J Clin Pathol"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"817086","DOI":"10.3389\/fcell.2021.817086","article-title":"Identification of prognostic biomarkers for bladder cancer based on DNA methylation profile.","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.3390\/ijms241512489","article-title":"Bladder epicheck test: a novel tool to support urothelial carcinoma diagnosis in urine samples.","volume":"24","author":"Fiorentino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40364-023-00488-3","article-title":"Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression.","volume":"11","author":"Shi","year":"2023","journal-title":"Biomark Res"},{"key":"R33-20260410","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/07357907.2022.2028805","article-title":"CD274 (PD-L1) methylation is an independent predictor for bladder cancer patients\u2019 survival.","volume":"40","author":"Xu","year":"2022","journal-title":"Cancer Invest"},{"key":"R34-20260410","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.humpath.2021.09.007","article-title":"Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples.","volume":"118","author":"Pierconti","year":"2021","journal-title":"Hum Pathol"},{"key":"R35-20260410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/diseases12090219","article-title":"The simultaneous use of bladder Epicheck\u00ae and urinary cytology can improve the sensitivity and specificity of diagnostic follow-up of urothelial lesions: up-to-date data from a multi-institutional cohort.","volume":"12","author":"Pepe","year":"2024","journal-title":"Diseases"},{"key":"R36-20260410","doi-asserted-by":"crossref","first-page":"131.e17","DOI":"10.1016\/j.urolonc.2020.06.018","article-title":"The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?","volume":"39","author":"Pierconti","year":"2021","journal-title":"Urol Oncol"},{"key":"R38-20260410","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2018.09.009","article-title":"Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy.","volume":"2","author":"Patterson","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"R39-20260410","doi-asserted-by":"crossref","first-page":"1051484","DOI":"10.3389\/fpubh.2023.1051484","article-title":"Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequential model.","volume":"11","author":"Zhao","year":"2023","journal-title":"Front Public Health"},{"key":"R40-20260410","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00345-025-06006-4","article-title":"Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China.","volume":"43","author":"Lin","year":"2025","journal-title":"World J Urol"},{"key":"R41-20260410","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clgc.2022.10.001","article-title":"Avelumab maintenance treatment after first-line chemotherapy in advanced urothelial carcinoma-a cost-effectiveness analysis.","volume":"21","author":"Lin","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"R42-20260410","doi-asserted-by":"crossref","first-page":"837854","DOI":"10.3389\/fpubh.2022.837854","article-title":"Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma.","volume":"10","author":"Xie","year":"2022","journal-title":"Front Public Health"},{"key":"R43-20260410","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1007\/s12325-021-01785-9","article-title":"Cost-effectiveness of atezolizumab plus chemotherapy as first-line therapy for metastatic urothelial cancer.","volume":"38","author":"Qin","year":"2021","journal-title":"Adv Ther"},{"key":"R44-20260410","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.clgc.2020.07.006","article-title":"Cost-effectiveness of pembrolizumab versus carboplatin-based chemotherapy as first-line treatment of PD-L1-positive locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.","volume":"19","author":"Hale","year":"2021","journal-title":"Clin Genitourin Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:22:00Z","timestamp":1785766920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":38,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048312","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2024-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}